The development of such molecules, able to reactivate a tumor suppressor gene like TP53, which is mutated in more than 50% of cancer cases, and which can also act on a target like NEDD9, which is particularly involved in the carcinogenesis process, offers hope for the development of new targeted therapies. Here, TP53 is linked to cancer.